<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03864913</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00017454</org_study_id>
    <nct_id>NCT03864913</nct_id>
  </id_info>
  <brief_title>Comparing Subcutaneous Testosterone to Intramuscular Testosterone in Gender Affirming Care of Transgender Male Adolescents</brief_title>
  <official_title>Investigating the Efficacy of Subcutaneous Testosterone Compared to Intramuscular Testosterone in Gender Affirming Care of Transgender Male Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial studies the efficacy of subcutaneous (SQ) testosterone compared to intramuscular
      (IM) testosterone therapy during the first 6 months of pubertal induction in transgender male
      adolescents. Describes rate of adverse effects, masculinizing effects and quality of life
      while receiving testosterone. Evaluates clinic utilization required for testosterone therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

        1. Determine the efficacy of SQ testosterone compared to IM testosterone therapy.
           Hypothesis: SQ testosterone is equally efficacious to IM testosterone in achieving
           mid-pubertal testosterone levels and masculinizing physical changes in transgender male
           adolescents after 6 months.

        2. Determine the rate of adverse reactions of SQ and IM testosterone during the first 6
           months of treatment.

           Hypothesis: SQ testosterone results in equal or fewer adverse reactions than IM
           testosterone.

        3. Evaluate quality of life (QOL) and satisfaction of injection technique for SQ and IM
           testosterone.

           Hypothesis: Subjects receiving SQ testosterone will report equal or superior quality of
           life and satisfaction with injection technique compared to IM testosterone as SQ is less
           painful and easier to administer at home.

        4. Evaluate and compare the number of clinical visits required for testosterone injections
           by transgender male patients receiving SQ and IM therapy.

      Hypothesis: Subjects using SQ testosterone will have fewer clinic visits than those using IM
      testosterone. This may impact healthcare-related costs.

      Study Outline:

      6 month study consisting of three study visits at baseline, 3 months and 6 months. Optional
      cross over of injection modality from 6-9 months. At each visit subjects complete blood work
      and questionnaires to determine testosterone peak and trough levels as well as biochemical
      adverse effects, quality of life, masculinizing effects and medication experience.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 26, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized arm (SQ, IM), as well as non-randomized SQ and non-randomized IM.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum testosterone level</measure>
    <time_frame>Two lab draws, before and after testosterone injection, drawn at 3 month and 6 month follow up</time_frame>
    <description>Trough and peak serum testosterone level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse effects</measure>
    <time_frame>Assessed at 3 month and 6 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PedsQL questionnaire score</measure>
    <time_frame>Completed at baseline, 3 month and 6 month follow up</time_frame>
    <description>Validated pediatric quality of life tool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Masculinizing effects</measure>
    <time_frame>Completed at 3 month and 6 month follow up</time_frame>
    <description>Self reported, questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication experience</measure>
    <time_frame>Completed at 3 month and 6 month follow up</time_frame>
    <description>Self reported, questionnaire</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Health Services for Transgender Persons</condition>
  <condition>Transgender Persons</condition>
  <arm_group>
    <arm_group_label>Randomized SQ vs IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to either SQ or IM testosterone injections follow study protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-randomized SQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects choose to participate in study, but decline to randomize and select SQ injections. Follow same study protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-randomized IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects choose to participate in study, but decline to randomize and select IM injections. Follow same study protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone injection</intervention_name>
    <description>SQ or IM testosterone injections for pubertal induction of transgender male adolescents. Increasing doses per protocol at 3 month and 6 month follow up.</description>
    <arm_group_label>Non-randomized IM</arm_group_label>
    <arm_group_label>Non-randomized SQ</arm_group_label>
    <arm_group_label>Randomized SQ vs IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PedsQL questionnarie</intervention_name>
    <description>Validated Pediatric Quality of Life questionnaire completed by subjects at baseline, 3 month and 6 month study visits.</description>
    <arm_group_label>Non-randomized IM</arm_group_label>
    <arm_group_label>Non-randomized SQ</arm_group_label>
    <arm_group_label>Randomized SQ vs IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Masculinizing effects questionnaire</intervention_name>
    <description>Subjects complete self-reported questionnaire at 3 month and 6 month study visits.</description>
    <arm_group_label>Non-randomized IM</arm_group_label>
    <arm_group_label>Non-randomized SQ</arm_group_label>
    <arm_group_label>Randomized SQ vs IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medication experience questionnaire</intervention_name>
    <description>Subjects complete self-reported questionnaire at 3 month and 6 month study visits.</description>
    <arm_group_label>Non-randomized IM</arm_group_label>
    <arm_group_label>Non-randomized SQ</arm_group_label>
    <arm_group_label>Randomized SQ vs IM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Testosterone naive

          -  Transgender male

          -  14-19 years old

        Exclusion Criteria:

          -  Transgender males who have received testosterone therapy in the past
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Transgender male</gender_description>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kara Connelly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Kara Connelly</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Gender affirming care</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

